Thomas Shrader
Stock Analyst at BTIG
(1.63)
# 3,214
Out of 4,761 analysts
45
Total ratings
41.03%
Success rate
-5.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARCT Arcturus Therapeutics Holdings | Initiates: Buy | $41 | $17.77 | +130.73% | 1 | Jan 28, 2025 | |
| ALEC Alector | Maintains: Buy | $16 → $5 | $1.87 | +167.38% | 2 | Nov 26, 2024 | |
| ATHA Athira Pharma | Downgrades: Neutral | n/a | $0.43 | - | 3 | Sep 4, 2024 | |
| PCVX Vaxcyte | Maintains: Buy | $98 → $160 | $79.74 | +100.65% | 4 | Sep 3, 2024 | |
| OVID Ovid Therapeutics | Maintains: Buy | $11 → $5 | $0.62 | +709.72% | 2 | Jun 18, 2024 | |
| ACIU AC Immune | Initiates: Buy | $8 | $2.65 | +201.89% | 1 | May 31, 2024 | |
| PMN ProMIS Neurosciences | Initiates: Buy | $8 | $0.82 | +881.60% | 1 | Oct 3, 2023 | |
| DTIL Precision BioSciences | Maintains: Buy | $180 → $60 | $5.93 | +911.80% | 1 | Jul 28, 2023 | |
| BHVN Biohaven | Reiterates: Buy | $24 | $36.91 | -34.98% | 2 | Jun 6, 2023 | |
| ANNX Annexon | Maintains: Buy | $15 → $7 | $2.81 | +149.11% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $6.41 | +134.01% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $0.41 | +3,085.49% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $31 | $67.96 | -54.38% | 3 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $2.27 | +340.53% | 2 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $1.39 | +1,482.73% | 2 | Oct 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $14 | $8.59 | +62.98% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $3.08 | +1,555.84% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.21 | +623.98% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.22 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $20.73 | - | 2 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $58 | $11.06 | +424.41% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $2.57 | +16.73% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $140.64 | +146.02% | 3 | Feb 21, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $4.35 | - | 1 | Jun 30, 2017 |
Arcturus Therapeutics Holdings
Jan 28, 2025
Initiates: Buy
Price Target: $41
Current: $17.77
Upside: +130.73%
Alector
Nov 26, 2024
Maintains: Buy
Price Target: $16 → $5
Current: $1.87
Upside: +167.38%
Athira Pharma
Sep 4, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.43
Upside: -
Vaxcyte
Sep 3, 2024
Maintains: Buy
Price Target: $98 → $160
Current: $79.74
Upside: +100.65%
Ovid Therapeutics
Jun 18, 2024
Maintains: Buy
Price Target: $11 → $5
Current: $0.62
Upside: +709.72%
AC Immune
May 31, 2024
Initiates: Buy
Price Target: $8
Current: $2.65
Upside: +201.89%
ProMIS Neurosciences
Oct 3, 2023
Initiates: Buy
Price Target: $8
Current: $0.82
Upside: +881.60%
Precision BioSciences
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $5.93
Upside: +911.80%
Biohaven
Jun 6, 2023
Reiterates: Buy
Price Target: $24
Current: $36.91
Upside: -34.98%
Annexon
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $2.81
Upside: +149.11%
May 18, 2023
Initiates: Buy
Price Target: $15
Current: $6.41
Upside: +134.01%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $0.41
Upside: +3,085.49%
Mar 20, 2023
Maintains: Buy
Price Target: $26 → $31
Current: $67.96
Upside: -54.38%
Nov 14, 2022
Maintains: Buy
Price Target: $30 → $10
Current: $2.27
Upside: +340.53%
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $1.39
Upside: +1,482.73%
May 24, 2022
Maintains: Buy
Price Target: $31 → $14
Current: $8.59
Upside: +62.98%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $3.08
Upside: +1,555.84%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $2.21
Upside: +623.98%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $4.22
Upside: -
Oct 16, 2020
Downgrades: Neutral
Price Target: n/a
Current: $20.73
Upside: -
Sep 15, 2020
Maintains: Buy
Price Target: $51 → $58
Current: $11.06
Upside: +424.41%
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $2.57
Upside: +16.73%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $140.64
Upside: +146.02%
Jun 30, 2017
Downgrades: Hold
Price Target: n/a
Current: $4.35
Upside: -